VNDAVanda Pharmaceuticals Inc.
5.280USD-5.21%Mkt Cap: 319.24M $P/E: —3d ago
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap319.24M $
Enterprise Value178.09M $
Revenue (TTM)215.72M $
Gross Profit203.06M $
Net Income (TTM)-220.47M $
Revenue/Share3.627 USD
Last Price5.280 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees533
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)26.90
PEG2.23
EV/EBITDA-1.01
EV/Revenue0.83
P/S1.51
P/B1.15
EPS (TTM)-4.47
EPS (Forward)0.20
52W Range
4.27018% of range9.940
52W High9.940 USD
52W Low4.270 USD
Profitability
Gross Margin93.96%
Oper. Margin-126.28%
EBITDA Margin-82.07%
Profit Margin-102.02%
ROE-67.38%
ROA-45.09%
Growth
Revenue Growth-3.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.44M $
CapEx (TTM)998.00K $
FCF Margin-40.20%
FCF Yield-27.16%
Net Debt-147.20M $
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity0.04
Current Ratio1.61
Quick Ratio1.40
Book Value/Sh4.669 USD
Cash/Share2.812 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.19 USD
Upside (mean)+130.8%
Target Range5.750 USD – 20.00 USD
$5.750+130.8% to mean$20.00
# Analysts4
Ownership
Shares Out.60.46M
Float51.04M
Insiders6.61%
Institutions83.47%
Short Interest
Short Ratio9.0d
Short % Float12.88%
Short % Out.12.28%
Shares Short7.42M
Short (prev mo.)7.34M
Technical
SMA 505.624 (-6.1%)
SMA 2006.522 (-19.0%)
Beta0.64
S&P 52W Chg18.16%
Avg Vol (30d)949.70K
Avg Vol (10d)1.09M
Technical Indicators
RSI (14)48.2
MACD-0.1038
MACD Signal-0.1702
MACD Hist.+0.0664
BB Upper5.469 USD
BB Middle5.176 USD
BB Lower4.883 USD
BB Width11.32%
ATR (14)0.2735 USD
Vol Ratio (20d)0.65x